This article is more than 5 years old. Information may no longer be current.
Pediatric Metabolic Liver Disorders: Diagnostic Challenges via Case Choice
Click Here to Manage Email Alerts
Genetic abnormalities affecting the synthesis or catabolism of metabolic enzymes can lead to the development of serious hepatic disorders. Although individually rare, the 2012 Organ Procurement and Transplantation Network report states that, collectively, metabolic liver diseases account for approximately 9% of pediatric liver transplantation cases in the United States. Because of the rare nature of these disorders, the nondescript symptoms at initial presentation, and provider unfamiliarity, many patients are easily misdiagnosed or unrecognized. In this activity, prominent clinicians will lead a discussion on the pathophysiology, symptomology, and differential diagnosis of pediatric hepato-metabolic disorders to assist providers in achieving appropriate diagnosis and effective disease management.
Learning Objectives:
Upon completion of this activity series, participants should be better able to:
- Summarize key elements and hallmarks of metabolic liver disorders in the pediatric population.
- Recognize the signs and symptoms of metabolic liver disorders and compare symptomatology in order to optimize differential diagnosis among hepatic and gastrointestinal disorders.
- Assess diagnostic modalities that effectively differentiate metabolic liver disorders that have similar symptoms, clinical characteristics, and laboratory presentations.
Click here to see this Education Lab Activity.
Overview
Author(s)/Faculty: Kathleen B. Schwarz, MD; Ryan W. Himes, MD; Maureen M. Jonas, MD; Jean Pappas Molleston, MD
Source: Healio Gastroenterology Education Lab
Type: Multimedia
Articles/Items: 6
Release Date: 12/26/2014
Expiration Date: 12/25/2015
Credit Type: CME
Number of Credits: 1.5
Cost: Free
Provider: Vindico
CME Information
Provider Statement: This continuing medical education activity is provided by Vindico.
Support Statement: This activity is supported by an educational grant from Synageva Biopharma. This was presented for attendees of the NASPGHAN Annual Meeting. This is not an official NASPGHAN event/function.
Target Audience: The intended audience for this activity is pediatric gastroenterologists and other health care professionals involved in the treatment of patients with metabolic liver disorders.